| Outcome Measures: |
Primary: Mean Change From Baseline in Hemoglobin Levels Over the Evaluation Period (Week 28 to Week 52), Blood samples were collected from participants for hemoglobin measurements. Hemoglobin during the evaluation period was defined as the mean of all available post-randomization hemoglobin values (on and off-treatment) during the evaluation period (Week 28 to Week 52). For the primary analysis, the missing post-Baseline hemoglobin values were imputed using pre-specified multiple imputations. Baseline value was the latest non-missing pre-dose assessment on or before the randomization date, including those from unscheduled visits. Change from Baseline was defined as the average of post-randomization values during the evaluation period minus Baseline value. Analysis was performed using the Analysis of Covariance (ANCOVA) model with terms for treatment, Baseline hemoglobin, and region., Baseline (Pre-dose on Day 1) and evaluation period (Week 28 to Week 52) | Secondary: Mean Average Monthly On-treatment Intravenous (IV) Iron Dose Per Participant, Average monthly IV iron dose (mg) per participant during Day 1 to Week 52 was determined by calculating the total IV iron dose per participant from Day 1 to Week 52 while the participant was on study treatment and dividing by (the number of days the participant was on study treatment divided by 30.4375 days). Analysis was performed using the ANCOVA model with terms for treatment, Baseline monthly IV iron dose, and region., Day 1 to Week 52|Change From Baseline in Hemoglobin Levels at Week 52, Blood samples were collected from participants for hemoglobin measurements. Baseline value was the latest non-missing pre-dose assessment on or before the randomization date, including those from unscheduled visits. Change from Baseline was defined as the post-randomization visit value minus Baseline value. Analysis was performed using a mixed model repeated measures (MMRM) model fitted to hemoglobin data collected after Baseline up to Week 52, excluding values collected during the stabilization period (Day 1 to Week 28). The model included factors for treatment, time, region, Baseline hemoglobin and Baseline hemoglobin by time and treatment by time interaction terms., Baseline (Pre-dose on Day 1) and Week 52|Percentage of Time With Hemoglobin in the Analysis Range (10 to 11.5 Grams/Deciliter) Over Evaluation Period (Week 28 to Week 52), Participants received treatment during the study to achieve or maintain hemoglobin level in the target range. Percentage of time for which hemoglobin level was maintained within the analysis range (10 to 11.5 grams/deciliter) has been presented., Week 28 to Week 52|Number of Hemoglobin Responders in the Hemoglobin Analysis Range (10 to 11.5 Grams/Deciliter) Over Evaluation Period (Week 28 to Week 52), Mean hemoglobin during the evaluation period was defined as the mean of all evaluable hemoglobin values during the evaluation period (Week 28 to Week 52) including any evaluable unscheduled hemoglobin values that were taken during this time period. Hemoglobin responders were defined as the number of participants with a mean hemoglobin during the evaluation period that falls within the hemoglobin analysis range of 10-11.5 grams/deciliter., Week 28 to Week 52|Percentage of Participants Permanently Stopping Study Treatment Due to Meeting Rescue Criteria, Percentage of participants permanently stopping study treatment due to meeting rescue criteria has been presented., Up to Week 52|Change From Baseline in Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP) and Mean Arterial Pressure (MAP) at Week 52, Measurements for SBP, DBP and MAP were taken with the participant in a semi-supine or seated position in the dialysis chair after at least a 5-minute rest period. MAP is the average BP in an individual's arteries during a single cardiac cycle. Baseline value was the latest non-missing pre-dose assessment on or before the randomization date, including those from unscheduled visits. Change from Baseline was defined as the on-treatment visit value minus Baseline value. Analysis was performed using MMRM model with treatment group, time, region, Baseline value, Baseline value\*time, treatment group\*time as variables., Baseline (Week -4 ) and Week 52|Change From Baseline in SBP, DBP and MAP at End of Treatment, Measurements for SBP, DBP and MAP were taken with the participant in a semi-supine or seated position in the dialysis chair after at least a 5-minute rest period. MAP is the average BP in an individual's arteries during a single cardiac cycle. Baseline value was the latest non-missing pre-dose assessment on or before the randomization date, including those from unscheduled visits. Change from Baseline was defined as the last on-treatment visit value minus Baseline value. Analysis was performed using ANCOVA model with terms for treatment group, region and Baseline value. Adjusted mean and standard error have been presented., Baseline (Week -4) and end of treatment (last on-treatment value until Week 52)|Blood Pressure (BP) Exacerbation Event Rate Per 100 Participant Years, BP exacerbation event is defined (based on post-dialysis BP) as SBP \>=25 mmHg increased from Baseline or SBP \>=180 mmHg; or DBP \>=15 mmHg increased from Baseline or DBP \>=110 mmHg. The BP exacerbation events per 100 participant years was estimated using the Negative Binomial Model., Up to 52 weeks|Number of Participants With at Least One BP Exacerbation Event During the Study, BP exacerbation (based on post-dialysis BP) is defined as: SBP \>= 25 mmHg increased from Baseline or SBP \>=180mmHg; or DBP \>=15 mmHg increase from Baseline or DBP \>=110 mmHg. Number of participants with at least 1 BP exacerbation event have been reported., Up to 52 weeks|Change From Baseline at Weeks 8, 12, 28 and 52 in Patient Global Impression of Severity (PGI-S), The PGI-S is a 1-item questionnaire designed to assess participant's impression of disease severity of their anemia of Chronic kidney disease (CKD). It is measured on a 5-point disease severity scale ranging from 0 (absent) to 4 (very severe), higher score indicates more disease severity. Baseline value was the latest non-missing pre-dose assessment on or before the randomization date, including those from unscheduled visits. Change from Baseline in on-treatment PGI-S scores was defined as the on-treatment visit value minus Baseline value. Analysis was performed using MMRM model fitted from Baseline up to Week 52 with factors for treatment, time, region, Baseline value and Baseline value by time and treatment by time interactions., Baseline (Pre-dose on Day 1) and Weeks 8, 12, 28, 52|Pre-dose Trough Concentration (Ctau) of Daprodustat (GSK1278863) and Its Metabolites GSK2391220 (M2), GSK2487818 (M4), GSK2506102 (M5), GSK2506104 (M3), GSK2531398 (M6) and GSK2531401 (M13), Blood samples were collected at indicated time points for pharmacokinetic analysis of daprodustat (GSK1278863) and its metabolites: GSK2391220 (M2), GSK2487818 (M4), GSK2506102 (M5), GSK2506104 (M3), GSK2531398 (M6) and GSK2531401 (M13)., Pre-dose on Day 1; Pre-dose and at 0.5, 1, 2, 3 hours post-dose on any one post-Baseline visit day between Week 8 and Week 52|Maximum Observed Concentration (Cmax) of Daprodustat (GSK1278863) and Its Metabolites GSK2391220 (M2), GSK2487818 (M4), GSK2506102 (M5), GSK2506104 (M3), GSK2531398 (M6) and GSK2531401 (M13), Blood samples were collected at indicated time points for pharmacokinetic analysis of daprodustat (GSK1278863) and its metabolites: GSK2391220 (M2), GSK2487818 (M4), GSK2506102 (M5), GSK2506104 (M3), GSK2531398 (M6) and GSK2531401 (M13)., Pre-dose on Day 1; Pre-dose and at 0.5, 1, 2, 3 hours post-dose on any one post-Baseline visit day between Week 8 and Week 52
|
| Locations: |
GSK Investigational Site, Mesa, Arizona, 85210, United States|GSK Investigational Site, Fresno, California, 93720, United States|GSK Investigational Site, Los Angeles, California, 90025, United States|GSK Investigational Site, Paramount, California, 90723, United States|GSK Investigational Site, Middlebury, Connecticut, 06762, United States|GSK Investigational Site, Hollywood, Florida, 33024, United States|GSK Investigational Site, Miami, Florida, 33169, United States|GSK Investigational Site, Tampa, Florida, 33614, United States|GSK Investigational Site, Macon, Georgia, 31201, United States|GSK Investigational Site, Meridian, Idaho, 83642, United States|GSK Investigational Site, Pittsfield, Massachusetts, 01201, United States|GSK Investigational Site, Kansas City, Missouri, 64111, United States|GSK Investigational Site, Saint Louis, Missouri, 63110, United States|GSK Investigational Site, Albuquerque, New Mexico, 87109, United States|GSK Investigational Site, College Point, New York, 11356, United States|GSK Investigational Site, Winston-Salem, North Carolina, 27103, United States|GSK Investigational Site, Oklahoma City, Oklahoma, 73116, United States|GSK Investigational Site, Houston, Texas, 77004, United States|GSK Investigational Site, Houston, Texas, 77099, United States|GSK Investigational Site, Lufkin, Texas, 75904, United States|GSK Investigational Site, Alexandria, Virginia, 22304, United States|GSK Investigational Site, Hampton, Virginia, 23666, United States|GSK Investigational Site, Norfolk, Virginia, 23510, United States|GSK Investigational Site, Mar del Plata, Buenos Aires, 7600, Argentina|GSK Investigational Site, Pergamino, Buenos Aires, B2700CPM, Argentina|GSK Investigational Site, Sarandi, Buenos Aires, B1872EEB, Argentina|GSK Investigational Site, Rosario, Santa Fe, 2000, Argentina|GSK Investigational Site, Heidelberg, Victoria, 3084, Australia|GSK Investigational Site, Parkville, Victoria, 3050, Australia|GSK Investigational Site, Salvador, Bahia, 40415-065, Brazil|GSK Investigational Site, Curitiba, Paraná, 80440-020, Brazil|GSK Investigational Site, Passo Fundo, Rio Grande Do Sul, 99010-080, Brazil|GSK Investigational Site, Porto Alegre, Rio Grande Do Sul, 90610-000, Brazil|GSK Investigational Site, Sao Jose do Rio Preto, São Paulo, 15090-000, Brazil|GSK Investigational Site, Belo Horizonte, Minas Gerais, 30150-221, Brazil|GSK Investigational Site, São Paulo, 04039-000, Brazil|GSK Investigational Site, Oshawa, Ontario, L1G 2B9, Canada|GSK Investigational Site, Bayonne, 64109, France|GSK Investigational Site, Epagny Metz-Tessy, 74370, France|GSK Investigational Site, Le Mans, 72037, France|GSK Investigational Site, Nice Cedex 1, 06001, France|GSK Investigational Site, Strasbourg, 67000, France|GSK Investigational Site, Bologna, Emilia-Romagna, 40138, Italy|GSK Investigational Site, Modena, Emilia-Romagna, 41124, Italy|GSK Investigational Site, Pavia, Lombardia, 27100, Italy|GSK Investigational Site, Verona, Veneto, 37126, Italy|GSK Investigational Site, Anyang-Si, Gyeonggi-do, 14068, Korea, Republic of|GSK Investigational Site, Busan, 49201, Korea, Republic of|GSK Investigational Site, Goyang-si, Gyeonggi-do, 10326, Korea, Republic of|GSK Investigational Site, Incheon, 405-760, Korea, Republic of|GSK Investigational Site, Seoul, 07061, Korea, Republic of|GSK Investigational Site, Seoul, 07441, Korea, Republic of|GSK Investigational Site, Seoul, 134-727, Korea, Republic of|GSK Investigational Site, Katowice, 40-027, Poland|GSK Investigational Site, Lodz, 92-213, Poland|GSK Investigational Site, Sandomierz, 27-600, Poland|GSK Investigational Site, Tarnowskie Gory, 42-612, Poland|GSK Investigational Site, Zyrardow, 96-300, Poland|GSK Investigational Site, Constanta, 900591, Romania|GSK Investigational Site, Resita, 320166, Romania|GSK Investigational Site, Kazan, 420012, Russian Federation|GSK Investigational Site, Kolomna, 140407, Russian Federation|GSK Investigational Site, Krasnodar, 350029, Russian Federation|GSK Investigational Site, Krasnogorsk, 143400, Russian Federation|GSK Investigational Site, Mytischi, 141009, Russian Federation|GSK Investigational Site, Novorossiysk, 353915, Russian Federation|GSK Investigational Site, Novosibirsk, 630087, Russian Federation|GSK Investigational Site, Omsk, 644111, Russian Federation|GSK Investigational Site, Orenburg, 460040, Russian Federation|GSK Investigational Site, Penza, 440034, Russian Federation|GSK Investigational Site, Podolsk, 142110, Russian Federation|GSK Investigational Site, Saint-Petersburg, 194354, Russian Federation|GSK Investigational Site, Saint-Petersburg, 197374, Russian Federation|GSK Investigational Site, St-Petersburg, 197110, Russian Federation|GSK Investigational Site, St. Petersburg, 193318, Russian Federation|GSK Investigational Site, St. Petersburg, 194104, Russian Federation|GSK Investigational Site, St. Petersburg, 196247, Russian Federation|GSK Investigational Site, Ufa, 450071, Russian Federation|GSK Investigational Site, Yaroslavl, 150062, Russian Federation|GSK Investigational Site, Almeria, 04009, Spain|GSK Investigational Site, Badalona, 08916, Spain|GSK Investigational Site, Barcelona, 08036, Spain|GSK Investigational Site, Gerona, 17007, Spain|GSK Investigational Site, Granollers, Barcelona, 08041, Spain|GSK Investigational Site, Madrid, 28100, Spain|GSK Investigational Site, Manises (Valencia), 46940, Spain|GSK Investigational Site, Sanlúcar De Barrameda (Cádiz), 11540, Spain|GSK Investigational Site, Bradford, BD5 0NA, United Kingdom|GSK Investigational Site, London, SE5 9RS, United Kingdom|GSK Investigational Site, Sheffield, S5 7AU, United Kingdom|GSK Investigational Site, Swansea, SA6 6NL, United Kingdom
|
